Central precocious puberty

Central precocious puberty, or CPP, is puberty that begins earlier than expected because the brain activates the body's normal puberty system too soon. This system involves signals between the brain, pituitary gland, ovaries or testes, and sex hormones.

Doctors often evaluate possible precocious puberty when typical pubertal changes begin before age 8 in girls or before age 9 in boys. Normal timing varies, so an early sign does not always mean a child has CPP.

CPP differs from isolated early breast development, body odor, or pubic hair. Those findings may occur without full activation of puberty. CPP generally causes progressive changes, faster growth, and advanced bone development.

Early puberty can affect growth and emotional well-being. Sex hormones make bones mature, so a child may grow quickly at first but stop growing earlier, potentially reducing adult height. Children may also feel unprepared for changes such as menstruation, facial hair, or a deeper voice.

Many cases, especially in girls, have no identifiable underlying disease. In others, CPP may be related to a condition affecting the brain. A pediatrician or pediatric endocrinologist can distinguish CPP from normal variations and other causes of early development.

CPP causes the same changes as typical puberty, but earlier. Changes usually progress over months.

In girls, the first sign is often breast development. Other signs include faster growth, widening hips, vaginal discharge, and eventually menstrual bleeding. Menstruation usually occurs later in puberty rather than being the first sign.

In boys, signs may include enlargement of the testes and penis, facial or body hair, a deeper voice, increased muscle development, and erections. Testicular enlargement is an important indication that the brain's puberty system may be active.

Children of any sex may develop:

• Rapid growth or greater height than peers
• Pubic or underarm hair
• Acne, oilier skin, or stronger body odor
• Mood or behavior changes
• Advanced bone development

Pubic hair, acne, or body odor alone may result from adrenal hormones. This is called premature adrenarche and is not the same as CPP. Mild breast development that does not progress may be a temporary variation called premature thelarche.

Early pubertal changes are usually not an emergency. Arrange a medical visit if puberty appears to begin before age 8 in a girl or age 9 in a boy, or if changes advance quickly.

Seek urgent assessment if early puberty occurs with persistent or severe headaches, repeated vomiting, vision changes, unusual thirst or urination, balance problems, weakness, or a major behavioral change. Call emergency services for a first seizure, loss of consciousness, sudden weakness, or a sudden severe headache.

CPP begins when the hypothalamus releases gonadotropin-releasing hormone, or GnRH. GnRH tells the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, which stimulate the ovaries or testes to produce sex hormones.

In many girls, no specific cause is found. This is called idiopathic CPP.

A brain or nervous system condition is more likely to be considered when puberty begins at a very young age, occurs in a boy, progresses rapidly, or appears with neurological symptoms. Possible causes include:

• A brain tumor or noncancerous growth, such as a hypothalamic hamartoma
• A congenital difference in brain development
• Hydrocephalus
• Previous brain infection, injury, surgery, or radiation
• Certain genetic conditions, including neurofibromatosis type 1
• Rare inherited changes affecting puberty control

Genetic counseling or testing may be considered when several relatives had unusually early puberty or the clinical pattern suggests an inherited cause.

Sex hormones from another source can also cause early changes. Examples include adrenal, ovarian, or testicular disorders and accidental exposure to estrogen or testosterone products. These are forms of peripheral precocious puberty, not CPP, although prolonged hormone exposure may eventually activate the central pathway.

Diagnosis begins with a medical history and physical examination. The clinician will ask when changes began, how quickly they progressed, and whether the child has headaches, vision problems, seizures, medication exposures, or a family history of early puberty.

Growth records are important. The clinician reviews height over time and examines breast or testicular development, pubic hair, skin changes, and other signs of puberty.

A bone-age X-ray of the left hand and wrist compares bone maturity with calendar age. Advanced bone age supports significant sex-hormone exposure but does not identify its cause.

Blood tests may measure luteinizing hormone, follicle-stimulating hormone, estradiol in girls, and testosterone in boys. Thyroid or other hormone tests may be added when another condition is suspected.

A sensitive luteinizing hormone test may support the diagnosis, but one random sample can miss early CPP. If the diagnosis remains uncertain, a GnRH or GnRH-agonist stimulation test can measure the pituitary gland's response after a stimulating medicine is given.

Pelvic ultrasound may be used in selected girls to examine the uterus and ovaries, but it cannot confirm or exclude CPP by itself. Testicular ultrasound or adrenal imaging may be appropriate if the examination or hormone results suggest another hormone source.

A brain MRI may be recommended to examine the hypothalamus and pituitary region. It is particularly important for children with neurological symptoms, boys with CPP, and very young girls. For girls whose puberty begins between ages 6 and 8 without concerning symptoms, MRI decisions are individualized.

The evaluation aims to determine:

• Whether full puberty is active
• How quickly it is progressing and whether it may affect height or well-being
• Whether an underlying condition is responsible

Not every child needs treatment. Slowly progressing changes, bone age close to calendar age, and little concern about adult height may support observation. The clinician may compare growth and development over several visits.

Progressive CPP is commonly treated with a GnRH agonist. Although these medicines initially stimulate the puberty pathway, continuous treatment makes the pituitary less responsive, lowers sex-hormone production, and pauses further pubertal progression.

GnRH agonists are available as scheduled injections or an implant placed under the skin. Choice depends on available products, the child's needs, access to care, and family preferences. A clinician experienced in pediatric puberty disorders should plan and monitor treatment.

Treatment goals may include:

• Preserving time for growth
• Slowing bone-age advancement
• Delaying menstruation or other later changes
• Reducing distress from developing far ahead of peers

Potential height benefit depends partly on the child's age and rate of progression. Treatment cannot guarantee a particular adult height, may not reverse established changes such as pubic hair, and does not treat an underlying brain condition.

Possible effects include injection-site pain or redness, headaches, hot flashes, and temporary mood changes. Pubertal signs may briefly increase when treatment begins, and girls may have light vaginal bleeding.

Contact the treating clinician promptly for severe or persistent headaches, vision changes, repeated vomiting, or other new neurological symptoms. Seek emergency care for a seizure, loss of consciousness, or a severe allergic reaction involving breathing difficulty or swelling.

Age-appropriate practical and emotional support is important. Children who menstruate early may need help using menstrual products. Counseling may be useful for anxiety, teasing, body-image concerns, or school difficulties.

Rapidly progressive CPP can advance bone age and close growth plates earlier. A child may initially be tall for their age but have a shorter adult height than expected from family patterns.

Early menstruation, erections, facial hair, or voice changes may cause embarrassment, unwanted attention, bullying, or distress, although not every child develops psychological difficulties.

Complications may also come from an underlying condition. For example, a growth near the brain's hormone-control centers can cause headaches, vision changes, or seizures. Research has not established that every child with CPP will have long-term reproductive, metabolic, or mental health problems.

During observation or treatment, follow-up usually includes height and weight measurements, growth-rate calculations, and assessment of pubertal development. Visits are often scheduled every few months, depending on the child's circumstances and treatment.

Hormone tests or a bone-age X-ray may be repeated when results would affect care; testing at every visit is not always necessary. Children receiving injections or an implant need timely doses or replacement.

Contact the endocrinology team if pubertal changes restart, menstrual bleeding continues, injections are missed, or medication effects are concerning. New headaches, vision changes, seizures, weakness, or balance problems need prompt assessment.

The decision to stop treatment considers age, bone age, height potential, emotional readiness, and family preferences. Puberty usually resumes after treatment ends, so the care team may continue monitoring growth and development.